Clinical Trials Logo
  1. Home
  2. Healthy
  3. NCT02309827
  4. Details
NCT02309827 Clinical Trial

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy Clinical Trial

Official title:
A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06651600 In Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02309827
Other study ID # B7981001
Secondary ID 2014-004326-17PF
Status Completed
Phase Phase 1
First received December 3, 2014
Last updated September 15, 2016
Start date December 2014
Est. completion date April 2016

Study information
Verified date September 2016
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

This study is a first in human study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test single and multiple doses of PF-06651600. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06651600 in healthy volunteers.

Recruitment information / eligibility
Status Completed
Enrollment 80
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of non-child bearing potential.

- BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

- Evidence of personally signed and dated informed consent document.

- Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures.

- Subjects must avoid high intensity UV light exposure (eg, active sunbathing, tanning beds/booths or sunlamps) from the first dose of study drug and for the duration of the study.

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.

- Use of tobacco/nicotine containing products in excess of 5 cigarettes/day.

- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.

- Screening blood pressure >140/90 mm Hg.

- Screening laboratory abnormalities as defined by the protocol.

- Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.

Study Design

Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• PF-06651600 or Placebo
PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Locations
Country Name City State
Belgium Pfizer Clinical Research Unit Brussels

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary 24 hour creatinine clearance (Single Dose) 24 hour urine creatinine clearance in healthy subjects participating in the single dose periods. For the single dose period, assessment occurs on Study Days 0 and 1. Single dose period, Day 0 (baseline) and 24 hours post dose Day 1. Yes
Primary 24 hour creatinine clearance (Multiple Dose) 24 hour urine creatinine clearance in healthy subjects participating in the multiple dose period. For the multiple ascending dose period assessments occur on Study Days 7 and 14. Multiple dose period, Days 0 (baseline), 7 and 14. Yes
Primary Change from baseline in urine volume (Single Dose) For the single dose period, assessment occurs on Study Days 0 and 1. Single dose period, Day 0 (baseline) and 24 hours post dose Day 1. Yes
Primary Change from baseline in urine electrolytes (Single Dose) For the single dose period, assessment occurs on Study Days 0 and 1. Single dose period, Day 0 (baseline) and 24 hours post dose Day 1. Yes
Primary Change from baseline in urine osmolality (Single Dose) For the single dose period, assessment occurs on Study Days 0 and 1. Single dose period, Day 0 (baseline) and 24 hours post dose Day 1. Yes
Primary Change from baseline of urine volume (Multiple Dose) For the multiple ascending dose period assessments occur on Study Days 7 and 14. Multiple dose period, Days 0 (baseline), 7 and 14. Yes
Primary Change from baseline of urine electrolytes (Multiple Dose) For the multiple ascending dose period assessments occur on Study Days 7 and 14. Multiple dose period, Days 0 (baseline), 7 and 14. Yes
Primary Change from baseline in urine osmolality (Multiple Dose) For the multiple ascending dose period assessments occur on Study Days 7 and 14. Multiple dose period, Days 0 (baseline), 7 and 14. Yes
Secondary Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Single Dose) Maximum Observed Plasma Concentration (Cmax) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Multiple Dose) Maximum Observed Plasma Concentration (Cmax) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Single Dose) Time to Reach Maximum Observed Plasma Concentration (Cmax) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600 (Multiple Dose) Time to Reach Maximum Observed Plasma Concentration (Cmax) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-06651600 (Single Dose) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06651600 (Single Dose) Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) for PF-06651600 (Single Dose) Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) for PF-06651600 (Multiple Dose) Dose Normalized Maximum Observed Plasma Concentration (Cmaxdn) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinfdn) for PF-06651600 (Single Dose) Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinfdn) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastdn) for PF-06651600 (Single Dose) Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastdn) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Plasma Decay Half-Life (t1/2) for PF-06651600 (Single Dose) Plasma Decay Half-Life (t1/2) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Plasma Decay Half-Life (t1/2) for PF-06651600 (Multiple Dose) Plasma Decay Half-Life (t1/2) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Mean Resonance Time (MRT) for PF-06651600 (Single Dose) Mean Resonance Time (MRT) 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Mean Resonance Time (MRT) for PF-06651600 (Multiple Dose) Mean Resonance Time (MRT) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Apparent Volume of Distribution (Vz/F) for PF-06651600 (Single Dose) Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Apparent Volume of Distribution (Vz/F) for PF-06651600 (Multiple Dose) Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Apparent Total Body Clearance (CL/F) for PF-06651600 (Single Dose) Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent total body clearance (CL/F) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose No
Secondary Apparent Total Body Clearance (CL/F) for PF-06651600 (Multiple Dose) Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent total body clearance (CL/F) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Minimum Observed Plasma Concentration (Cmin) for PF-06651600 (Multiple Dose) Minimum Observed Plasma Concentration (Cmin) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Average Concentration for Dosing Interval (12 or 24 hours) (Cav) for PF-06651600 (Multiple Dose) Average Concentration for Dosing Interval (12 or 24 hours) (Cav) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Area Under the Curve for Dosing Interval (12 or 24 hours) for PF-06651600 (Multiple Dose) Area Under the Curve for Dosing Interval (12 or 24 hours) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Dose Normalized Area Under the Curve for Dosing Interval (12 or 24 hours) for PF-06651600 (Multiple Dose) Dose Normalized Area Under the Curve for Dosing Interval (12 or 24 hours) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Peak to Trough Fluctuation (PTF) for PF-06651600 (Multiple Dose) Peak to Trough Fluctuation (PTF) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Observed Accumulation Ratio (Rac) for PF-06651600 (Multiple Dose) Observed Accumulation Ratio (Rac) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Observed Accumulation Ratio for Cmax (RacCmax) for PF-06651600 (Multiple Dose) Observed Accumulation Ratio for Cmax (RacCmax) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Steady State Accumulation Ratio (Rss) for PF-06651600 (Multiple Dose) Steady State Accumulation Ratio (Rss) Days 1, 4, 6, 8, 10, 12 and 14 (0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48 hours post dose) No
Secondary Amount of PF-066561600 Excreted Unchanged (Multiple Dose) Concentration in urine. Day 14 (12, 24 hours post dose) No
Secondary Change from baseline of BCL2 gene expression in whole blood (Single Dose) Days -1 and 1 (0, 1, 2, 4, 8, 12 and 24 hours post dose) No
Secondary Change from baseline of BCL2 gene expression in whole blood (Multiple Dose) Days 1, 5, 10, 14 (0, 1, 2, 4, 8, 12 and 24 hours post dose), 16, and 28 No
Secondary Change from baseline of IP-10 protein concentration in serum (Multiple Dose) Days 0, 2, 7, 14 (0, and 16 hours post dose) and 16 No
Secondary Change from baseline of hsCRP protein concentration in serum (Multiple Dose) Days 0, 2, 7, 14 (0, and 16 hours post dose) and 16 No
Secondary Change from baseline of reticulocyte counts in whole blood (Single Dose) Days 0, 2, 3, and 7 Yes
Secondary Change from baseline of neutrophil counts in whole blood (Single Dose) Days 0, 2, 3, and 7 Yes
Secondary Change from baseline of hemoglobin level whole blood (Single Dose) Days 0, 2, 3, and 7 Yes
Secondary Change from baseline of reticulocyte counts in whole blood (Multiple Dose) Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28 Yes
Secondary Change from baseline of neutrophil counts in whole blood (Multiple Dose) Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28 Yes
Secondary Change from baseline of hemoglobin level in whole blood (Multiple Dose) Days 0, 4, 8, 12, 14 (pre-dose) 15, and 28 Yes
Secondary Renal Clearance (Multiple Dose) Day 1, Day 14 (12, 24 hours post dose) No
Secondary Percentage of PF-066561600 Excreted Unchanged (Multiple Dose) Concentration in urine. Day 14 (12, 24 hours post dose) No
Secondary Change from baseline of IP-10 gene expression in blood (Multiple Dose) Days 0, 5, 10, 14 (0, 1, 2, 4, 8 and 12 hours post dose) and 16 No
Secondary Change from baseline of IP-10 gene expression in blood (Single Dose) Days 0, 1 (0, 1, 2, 4, 8 and 12 hours post dose) and 16 No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links